000030625 001__ 30625
000030625 005__ 20131002114018.0
000030625 0248_ $$aoai:doc.rero.ch:20121116084407-NY$$punifr$$ppostprint$$prero_explore$$zcdu34$$zthesis_urn$$zcdu57$$zreport$$zthesis$$zbook$$zjournal$$zcdu16$$zpreprint$$zcdu1$$zdissertation
000030625 041__ $$aeng
000030625 080__ $$a57
000030625 100__ $$aYang, Zhihong$$uLaboratory of Vascular Biology, Division of Physiology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
000030625 245__ $$9eng$$amTOR signalling: the molecular interface connecting metabolic stress, aging and cardiovascular diseases
000030625 269__ $$c2012-10-29
000030625 520__ $$9eng$$aThe continuing increase in the prevalence of obesity and metabolic disorders such as type-II diabetes and an accelerating aging population globally will remain the major contributors to cardiovascular mortality and morbidity in the 21st century. It is well known that aging is highly associated with metabolic and cardiovascular diseases. Growing evidence also shows that obesity and metabolic diseases accelerate aging process. Studies in experimental animal models demonstrate similarity of metabolic and cardiovascular phenotypes in metabolic diseases and old age, e.g. insulin resistance, oxidative stress, chronic low grade inflammation, cardiac hypertrophy, cardiac fibrosis, and heart failure, as well as vascular dysfunctions. Despite intensive research, the molecular mechanisms linking metabolic stress, aging, and ultimately cardiovascular diseases are still elusive. Although the mammalian target of rapamycin (mTOR) signalling is a well known regulator of metabolism and lifespan in model organisms, its central role in linking metabolic stress, aging and cardiovascular diseases is recently emerging. In this article, we review the evidence supporting the role of mTOR signalling as a molecular interface connecting metabolic stress, aging and cardiovascular diseases. The therapeutic potentials of targeting mTOR signalling to protect against metabolic and age-associated cardiovascular diseases are discussed.
000030625 695__ $$9eng$$aAging ; cardiovascular diseases ; mTOR ; obesity
000030625 700__ $$aMing, Xiu-Fen$$uLaboratory of Vascular Biology, Division of Physiology, Department of Medicine, Faculty of Science, University of Fribourg, Switzerland
000030625 773__ $$g2012/13/S2/58–68$$tObesity Reviews
000030625 775__ $$gPublished version$$ohttp://dx.doi.org/10.1111/j.1467-789X.2012.01038.x
000030625 8564_ $$fyan_msm.pdf$$qapplication/pdf$$s665386$$uhttp://doc.rero.ch/record/30625/files/yan_msm.pdf$$yorder:1$$zpdf
000030625 918__ $$aFaculté des sciences$$bDécanat, Ch. du Musée 6A, 1700 Fribourg$$cMédecine
000030625 919__ $$aUniversité de Fribourg$$bFribourg$$ddoc.support@rero.ch
000030625 980__ $$aPOSTPRINT$$bUNIFR$$fART_JOURNAL
000030625 990__ $$a20121116084407-NY